Upgrade to SI Premium - Free Trial

Teva (TEVA): Soft 2Q Underscores Need For Actavis - Piper Jaffray

August 5, 2016 9:03 AM
Piper Jaffray analyst David Amsellem bumped his price target on Teva Pharma (NYSE: TEVA) to $57.00 (from $55.00) but maintained ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Next Articles